Tumor-infiltrating lymphocytes in triple negative breast cancer: The future of immune targeting

Clinical Medicine Insights: Oncology

Volumn 10, Issue , 2016, Pages 31-39

  García Teijido, Paula ^a   Cabal, María Luque ^b   Fernández, Ignacio Peláez ^c   Pérez, Yolanda Fernández ^b  

^a HOSPITAL SAN AGUSTÍN   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Breast cancer (BC); Prognosis; Programmed cell death ligand 1 (PD L1); Triple negative (TN); Tumor infiltrating lymphocytes (TILs)

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ATEZOLIZUMAB; BEVACIZUMAB; CARBOPLATIN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; IMMUNOMODULATING AGENT; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMBROLIZUMAB; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TAXANE DERIVATIVE; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; META ANALYSIS (TOPIC); MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84988378157     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S34540     Document Type: Review

References (53)

1. Zitvogel L, Apetoh L, Ghiringhelli F, etal. The anticancer immune response: indispensable for therapeutics success? J Clin Investig. 2008;118:1991–2001, doi:10.1172/JCI35180.
2. Dunn G, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.
3. Disis ML, Stanton SE. Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm. 2015ASCO Educational Book. Asco.org/edbook.
4. Demaria S, Volm MD, Shapiro RL, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clinical Cancer Res. 2001;7:3025–30
5. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–3.
6. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(3):860–67.
7. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: the FinHER trial. Ann Oncol. 2014;25:1544–50.
8. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocites in triple negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–67.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
10. Wimberly H, Brown JR, Schalper KA, et al. PD-L1 expression correlation with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3(4):326–32.
11. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Presented at San Antonio Breast Cancer Symposium. December 9–13, 2014. San Antonio, TX.
12. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
13. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5:5–23.
14. Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 2015, http://dx.doi.org/10.1016/j.breast.2015.07.008.
15. Lehman BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Clin Invest. 2011;121(7):2750–67. doi:10.1172/JCI45014.
16. Bunstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Res. 2015; 21:1688–98.
17. Carey L, Winer E, Viale G, et al. Triple negative cancer: disease entity or title convenience? Nat Rev Clin Oncol. 2010;7:683–92.
18. Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Rev in Clin Oncol. published on line 15 Dec 2015. Doi: 10.1038/nrclinonc.2015.215.
19. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs Working Group 2014. Ann Oncol. 2015;26:259–71.
20. Denkert C, Minckwitz G, Brasen JA, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple negative primary breast cancers. J Clin Oncol. 2015;33:983–1.
21. Pruneri G, Vingiani A, Bagnardi V, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple negative breast cancer. Ann Oncol Advance Access published November 23, 2015.
22. Cimino-Mathews A, Foote JB, Emns LA, et al. Immune targeting in breast cancer. Oncology (Willston Park). 2015;29:375–85.
23. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
24. Liu S, Lachapelle J, Leung S, et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48. http://breast-cancer-research.com/content/14/2/R48
25. West NR, Kost SE, Martin SD, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108, 155–62 | doi: 10.1038/bjc.2012.524
26. Ali HR, Provenzano E, Dawson E, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25:1536–43.
27. Chen Z, Chen X, Zhou E, et al. Intratumoral CD8(+) cytotoxic lymphocyte is a favourable prognostic marker in node-negative breast cancer. PLoS One. 2014; 9(4):e95475. doi: 10.1371/journal.pone.0095475.
28. Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793–805.
29. Mao Y, Zhang Y, et al. The value of tumor-infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e115103.
30. Tung NM, Winer E. Tumor-infiltrating lymphocytes and response to platinum in Triple-Negative Breast Cancer. J Clin Oncol. 2015;33:969–71.
31. Roselli m, Cereda V, di Bari MG, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013; 2:e26440; 10.4161/onci.26440.
32. Jäger D, Jäger E, Knuth A. Immune responses to tumour antigens implications for antigen specific immunotherapy of cancer. J Clin Pathol. 2001;54:669–74.
33. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrat ing immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.
34. Cortázar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2015;384;164–72.
35. Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611–18.
36. García-Martínez E, Luengo G, Chaves A, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res, 2014;16;488.
37. Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Research. 2015;17:124.
38. Drake CG, Lipson EJ and Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11:24–37. Doi:10.1038/ncrlinonc.2013.208.
39. Raufi AG and Kemplern SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015;6:561–69.
40. Nanda R, Chow LQ, Dees EC, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9–13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 2015;75(9 Suppl):Abstract nr S1–09.
41. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in with metastatic triple-negative breast cancer (TNBC). [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015Apr 18–22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res. 2015;75(15 Suppl):Abstract nr 2859. doi:10.1158/1538-7445.AM2015-859.
42. Adams S, Diamond J, Hamilton E, Pohlmann, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. “[abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 2016;76(4 Suppl):Abstract nr OT1-01-06.
43. Schalper KA, Velcheti V, Carbajal D, et al. In situ tumorPD-L1mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773–8.
44. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107–6.
45. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
46. Ghebeh H, Mohammed S, Al Omair A, et al. The B7-H1 T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190–98.
47. Muenst S, Soysal SD, Gao F, et al. The presence of programmed cell death (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139. doi:10.1007/s10549-013-2581-3.
48. Mittendorf EA, Philips AV, Meric-Bemstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70. doi: 10.1158/2326-6066.CIR-13-0127.
49. Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2014;6:5449–64.
50. Beckers RK, Selinger CI, Vilain R, et al. PDL1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Accepted Article, doi 10.1111/his.12904.
51. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
52. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. doi:10.1038/nature13954.
53. Taube JM, Klein A, Brahmenr JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–74. doi:10.1158/1078–0432.CCR-13–3271.